Investment House LLC Raises Position in Solventum Co. (NYSE:SOLV)

Investment House LLC raised its stake in shares of Solventum Co. (NYSE:SOLV - Free Report) by 111.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,171 shares of the company's stock after purchasing an additional 40,130 shares during the period. Investment House LLC's holdings in Solventum were worth $5,032,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of SOLV. Atria Investments Inc raised its stake in shares of Solventum by 93.2% in the third quarter. Atria Investments Inc now owns 11,699 shares of the company's stock valued at $816,000 after acquiring an additional 5,644 shares during the period. Victory Capital Management Inc. grew its holdings in Solventum by 137.3% during the 3rd quarter. Victory Capital Management Inc. now owns 53,589 shares of the company's stock valued at $3,736,000 after purchasing an additional 31,007 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Solventum in the 3rd quarter worth about $315,000. CIBC Asset Management Inc lifted its stake in Solventum by 7.9% in the third quarter. CIBC Asset Management Inc now owns 19,291 shares of the company's stock worth $1,345,000 after purchasing an additional 1,408 shares during the last quarter. Finally, Natixis Advisors LLC boosted its position in shares of Solventum by 271.4% during the third quarter. Natixis Advisors LLC now owns 47,616 shares of the company's stock valued at $3,320,000 after buying an additional 34,797 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SOLV. Wells Fargo & Company increased their price target on Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. Mizuho lifted their target price on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research report on Monday, March 3rd. Morgan Stanley upped their price target on shares of Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th. The Goldman Sachs Group raised their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research note on Monday, March 3rd. Finally, Bank of America boosted their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $79.86.

Remove Ads

Solventum Stock Down 1.3 %

NYSE SOLV traded down $0.99 during trading on Friday, reaching $74.00. 1,919,810 shares of the company's stock traded hands, compared to its average volume of 1,429,530. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a market cap of $12.80 billion and a price-to-earnings ratio of 26.91. The company's 50 day simple moving average is $75.17 and its two-hundred day simple moving average is $71.56.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.